跳到正文
原文
Nature Medicine· Timothy A. Yap·· 2026-09-29AI 评分55

RO7589831 治疗微卫星不稳定实体瘤的 I 期试验:剂量递增阶段未达最大耐受剂量,观察到部分缓解

Werner helicase inhibitor for advanced microsatellite instability solid tumors: a phase 1 trial

AI 导读

一项评估 RO7589831 的 I 期试验在微卫星不稳定和/或 DNA 错配修复缺陷实体瘤患者中完成剂量递增阶段。RO7589831 是靶向合成致死靶点 Werner 综合征解旋酶(WRN)的首创抑制剂。该阶段未达到最大耐受剂量,并观察到部分缓解。

正文

Nature Medicine, Published online: 29 September 2026; doi:10.1038/s41591-026-04657-3

In the dose-escalation stage of a phase 1 trial evaluating RO7589831, a first-in-class inhibitor of the synthetic lethal target Werner syndrome helicase, in patients with microsatellite instability and/or DNA mismatch repair-deficient solid tumors, the maximum tolerated dose was not reached and some partial responses were observed.

来源:Nature Medicine · nature.com